LineMatrix® Biological Vascular Graft for the Creation of Arteriovenous Graft
A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 326 participants.
Also called NCT07773051
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 326 participants
- Sponsor
- Longhua Hospital
- Registry
-
NCT07773051
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07773051. Randomized; no masking; primary purpose treatment. Start 2025-08-25 (actual); primary completion 2027-06-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- LineMatrix® Biological Vascular Graft for the Creation of Arteriovenous Graft
- Condition
- Arteriovenous Graft
- Intervention (Device)
- LineMatrix® Biological Vascular Graft
- Intervention (Device)
- GORE-INTERING®
- Lead sponsor
- Longhua Hospital
- Collaborator
- Humatrix Medical Technology (Suzhou) Co., LTD
Record details
- Record id
cardio:ct-nct07773051- Content hash
fb6a0a64aa68a3fb96330be4ce610609231a09ff4d794ba02846af193d257093